[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366592-105":59,"doc-detail-366592-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","differential-parp-inhibitor-responses-in-brca1-deficient-and-resistant-cells-in-competitive-co-culture","Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture","","Synthetic lethality describes a genetic interaction in which combined loss of two genes causes cell death while loss of either gene alone does not. Precision oncology exploits these relationships, particularly PARP inhibitors that preferentially kill BRCA1-deficient tumors over BRCA1-proficient cells. This study introduces a competitive co-culture assay to evaluate drugs or gene knockouts with synthetic lethal effects. BRCA1 isogenic pairs were labeled with distinct fluorescent reporters, co-cultured, dosed with four PARP inhibitors, and quantified by flow cytometry. Results show selective PARPi targeting of BRCA1-deficient cells and subtle differences between resistant lines compared with BRCA1-proficient cells.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/differential-parp-inhibitor-responses-in-brca1-deficient-and-resistant-cells-in-competitive-co-culture/366592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/differential-parp-inhibitor-responses-in-brca1-deficient-and-resistant-cells-in-competitive-co-culture/366592.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is synthetic lethality and why is it important for PARP inhibitors?","Question",{"text":112,"@type":113},"Synthetic lethality is a genetic relationship where loss of two genes leads to cell death, while loss of one does not. PARP inhibitors exploit this by preferentially targeting tumors with BRCA1 deficiencies compared with BRCA1-proficient cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the competitive co-culture assay work in this study?",{"text":117,"@type":113},"BRCA1 isogenic cell line pairs were labeled with fluorescent reporters, grown together in the same vessel to create a competitive environment, treated with PARP inhibitors, and analyzed by counting fluorescent cells using flow cytometry.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the researchers observe when testing PARP inhibitors on BRCA1-deficient versus resistant cells?",{"text":121,"@type":113},"PARP inhibitors preferentially targeted BRCA1-deficient cells at concentrations broadly reflecting clinical dosing. The study also revealed subtle differences between PARPi-resistant lines and BRCA1-proficient cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366592,1790197982,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","OPEN ACCESS  \nCitation: Soetomo SA, Sharp MF, Crismani W (2025) Differential PARP inhibitor responsesin BRCA1-deficient and resistant cells in competitive co-culture. PLoS One 20(9):  \ne0332860. [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0332860  \nEditor: Zu Ye, Zhejiang Cancer Hospital, CHINA  \nReceived: May 14, 2025  \nAccepted: September 4, 2025  \nPublished: September 22, 2025  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0332860  \nCopyright: © 2025 Soetomo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nRESEARCH ARTICLE  \nDifferential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture  \nShiella A. Soetomo1,2‡, Michael F. Sharp1,2‡, Wayne Crismani1,2*  \n1 St Vincent’s Institute of Medical Research, Fitzroy, Victoria, Australia, 2 The Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, Australia  \n‡ Shiella Soetomo and Michael Sharp should be recognised as co-first authors.  \n* [wcrismani@svi.edu.au](wcrismani@svi.edu.au)  \nAbstract  \nSynthetic lethality describes a genetic relationship where the loss of two genes results in cell death, but the loss of one of those genes does not. Drugs used for precision oncology can exploit synthetic lethal relationships; the best described are PARP inhibitors which preferentially kill BRCA1-deficient tumours preferentially over BRCA1-proficient cells. New synthetic lethal targets are often discovered using genetic screens, such as CRISPR knockout screens. Here, we present a competitive co-culture assay that can be used to analyse drugs or gene knockouts with synthetic lethal effects. We generated new BRCA1 isogenic cell line pairs from both a  \ntriple-negative breast cancer cell line (SUM149) and adapted pre-existing noncancerous BRCA1 isogenic pair (RPE) . Each cell line of the isogenic pair was transformed with its own fluorescent reporter. The two-coloured cell lines of the isogenic pair were then grown together in the same vessel to create a more competitive environment compared to when grown separately. We used four PARP inhibitors to validate the ability to detect synthetic lethality in BRCA1-deficient cancer cells. The readout of the assay was performed by counting the fluorescently coloured cells after drug treatment using flow cytometry. We observed preferential targeting of BRCA1-deficient cells, by PARPi, at relative concentrations that broadly reflect clinical dosing. Further we reveal subtle differences between PARPi resistant lines compared to BRCA1-proficient cells. Here, we demonstrate the validation and potential use of the competitive assay, which could be extended to validating novel genetic relationships and adapted for live cell imaging.  \nIntroduction  \nCancer cells can have genetic driver mutations that can make them heavily reliant on certain pathways for survival [ 1] . By targeting a second complementary gene or pathway that is synthetic lethal with the cancer-specific mutation, specific inhibitors can  \nPLOS One | [https://doi.org/10.1371/journal.pone.0332860](https://doi.org/10.1371/journal.pone.0332860) September 22, 2025 1 / 12  \nData availability statement: The data is attached to this revised submission.  \nFunding: W.C. receives a fellowship related to this work from the Victorian Cancer Agency (MCRF21006) . SVI receives Operational Infrastructure Support from the Victorian State Government. S.S. received an Indonesian Lembaga Pengelola Dana Pendidikan ","cbCaioXk6jgRQox0","https://ap.wps.com/l/cbCaioXk6jgRQox0","pdf",1311768,12,"English","# Abstract\n## Introduction\n## Data availability and funding","[{\"question\":\"What is synthetic lethality and why is it important for PARP inhibitors?\",\"answer\":\"Synthetic lethality is a genetic relationship where loss of two genes leads to cell death, while loss of one does not. PARP inhibitors exploit this by preferentially targeting tumors with BRCA1 deficiencies compared with BRCA1-proficient cells.\"},{\"question\":\"How does the competitive co-culture assay work in this study?\",\"answer\":\"BRCA1 isogenic cell line pairs were labeled with fluorescent reporters, grown together in the same vessel to create a competitive environment, treated with PARP inhibitors, and analyzed by counting fluorescent cells using flow cytometry.\"},{\"question\":\"What did the researchers observe when testing PARP inhibitors on BRCA1-deficient versus resistant cells?\",\"answer\":\"PARP inhibitors preferentially targeted BRCA1-deficient cells at concentrations broadly reflecting clinical dosing. The study also revealed subtle differences between PARPi-resistant lines and BRCA1-proficient cells.\"}]","Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture | PDF",1790166300,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7246d4836a03db041997da6f6c5bcb6e.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7d42d9a7212add915658507443847e6.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb17ed884e2bbd64a97764e05106fe59.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf8e58f509e0188e3a42bde05a665d00.webp",980,1268]